Abstract
Pancreatic cancer is a highly malignant tumor with early metastasis, poor prognosis, and resistant to existing chemotherapy drugs such as oxaliplatin (Oxp). Therefore, a nanodrug of amorphous iron oxide packaged Oxp (AIOoxp) was proposed to achieve a more efficient treatment of orthotopic pancreatic cancer than that of free Oxp. The obtained AIOoxp increased the accumulation of Pt at tumor sites and effectively reduced Oxp-induced systemic toxicity. In addition, the Fe2+/Fe3+ ions released by AIOoxp react with H2O2 through Fenton’s reaction and produce a large amount of reactive oxygen species (ROS), which further induce ferroptosis, thus promoting Oxp-induced apoptosis and achieve synergistic tumor therapy. Furthermore, AIOoxp nanoplatforms can significantly reduce the levels of carbohydrate antigen 19–9 (CA19-9), which is the most important biomarker and promoter of pancreatic cancer, suggesting favorable therapeutic effects and prognosis. Overall, this study provides new insights and solutions for the clinical treatment of pancreatic cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
